GammaPod revolutionizes breast cancer treatment: Italy introduces high-dose stereotactic radiotherapy in a single session to Europe

GammaPod represents a true revolution in the treatment of breast cancer: it allows the safe and precise administration of high doses of radiation to the tumor because, unlike conventional radiotherapy equipment, designed to treat tumors in all areas of the body, GammaPod was invented and designed to treat only breast cancer. For this reason, it is able to concentrate the entire dose on the tumor alone, drastically reducing exposure and damage to surrounding healthy tissue, thus minimizing side effects. This allows the tumor to be treated with a much higher dose of radiation until it is destroyed, in a single fraction.

Italy, 29/04/2025 (informazione.news - comunicati stampa - salute e benessere)

: it allows the safe and precise administration of high doses of radiation to the tumor because, unlike conventional radiotherapy equipment, designed to treat tumors in all areas of the body, . This allows the tumor to be treated with a much higher dose of radiation until it is destroyed, .

This non-invasive, single-fraction approach, replacing the numerous fractions used with conventional equipment, offers patients a rapid therapeutic path with .

The clinical study conducted at the hospital in Udine was recently published in the prestigious ( ) which demonstrated that in the pre-operative treatment of breast cancer, with a significant reduction in the cell proliferation index (Ki-67), an important marker for evaluating the tumour response to radiotherapy.

"The results are extraordinary," says , Director of Radiotherapy at the Udine hospital. "GammaPod allows us to administer a very high dose of radiation in a single session, with a clear biological response, as indicated by the drop in Ki-67."

On , GammaPod will be the star of the "Reducing the Impact of Breast Cancer," organized by Tema Sinergie during the in . The session will feature international experts, including , who will delve into the technology's features, and , who will present the results of their respective clinical studies. The symposium will be moderated by and .

Tema Sinergie's commitment to introduce this technology in Europe underscores the importance of international collaboration in bringing new patient care solutions to the market. With this commitment, GammaPod is set to become a key pillar in the fight against breast cancer worldwide.

https://www.gammapod.eu

https://www.redjournal.org/article/S0360-3016(25)00152-X/abstract

https://www.temasinergie.com

Video - https://mma.prnewswire.com/media/2673502/Tema_Sinergie_GammaPod.mp4
Logo - https://mma.prnewswire.com/media/2673488/Tema_Sinergie_Logo.jpg

Stefano Camanzi
marketing@temasinergie.com
+39 0546 622 663

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/gammapod-revolutionizes-breast-cancer-treatment-italy-introduces-high-dose-stereotactic-radiotherapy-in-a-single-session-to-europe-302441037.html